The UCL spinout has priced its shares at the top of its range and secured $150m in proceeds, up from its initial target of $100m.

Autolus, a UK-based cancer-focused biopharmaceutical spinout from University College London (UCL), priced its shares at the top of its range at $17 on Friday and raised $150m in proceeds.

The company issued approximately 8.8 million American Depositary Shares (ADS) on Nasdaq, with each ADS representing one share. It had originally planned to issue 7.8 million ADS.

The $150m figure represents an increase over the spinout’s initial target of $100m. Underwriters have a 30-day option to purchase an additional…